INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
03 · Corporate insiders

Form 4 filings

Officers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.

Form 4 transactions

Cluster activity · 60d

Most active filers

Companies with the most Form 4 filings
Data sources
SEC Form 42h ago
House PTR2h ago
SEC 13F2h ago
Robinhood Chain2h ago

Most active filers · 30d

  1. 01Kurtz George0B / 220S220 trades$52.89M
  2. 02SPSaba Capital Management, L.P.66B / 18S · 11 late84 trades$24.31M
  3. 03SJSheena Jonathan0B / 57S57 trades$3.61M
  4. 04ATAdair Kathleen Theresa52B / 0S · 52 late52 trades$18K
  5. 05AJAllaire Jeremy0B / 50S50 trades$4.26M
  6. 06Wilhelmsen Arne Alexander0B / 47S47 trades$241.96M
  7. 07SLSpeiser Michael L0B / 35S35 trades$14.00M
  8. 08RARothblatt Martine A0B / 33S33 trades$5.50M
  9. 09RJRubinstein Julie0B / 32S32 trades$5.48M
  10. 10CECrimmins David Edward0B / 31S31 trades$723K

Cluster activity · 60d

  1. BUYTSMTAIWAN SEMICONDUCTOR MANUFACTURING CO LTDNov 5 – Nov 631 insiders$417K
  2. SELLDRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
  3. BUYMTDRMatador Resources CoNov 5 – Nov 109 insiders$765K
  4. SELLMSIMotorola Solutions, Inc.Nov 6 – Nov 108 insiders$40.91M
  5. SELLFFIVF5, INC.Nov 3 – Nov 58 insiders$8.37M
  6. SELLMGNIMAGNITE, INC.Nov 5 – Nov 127 insiders$2.27M
  7. SELLSYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M
  8. BUYUPBDUPBOUND GROUP, INC.Nov 2 – Nov 37 insiders$1.34M

Form 4 transactions

69,544 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
Include
grants & admin
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
NJ
Nance Jeremy JohnSVP and General Counsel
VVXV2X, Inc.
Tax withholding
F$31K
440 sh
Mar 12, 2026Mar 13, 2026
Page 1125 of 1739
← PrevNext →
traded Mar 12, 2026
+1d
SEC Form 4

Evidence

9
FG
Foletta Mark GDirector
ENTAENANTA PHARMACEUTICALS INC
Grant or award
A—
20.0K sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC Form 4

Evidence

9
VA
Villanueva Rodriguez AlfonsoEVP&Int.Group CEO-VZ Cons.&CTO
VZVERIZON COMMUNICATIONS INC
Grant or award
A$1,046
72 sh
Mar 12, 2026Mar 13, 2026
traded Mar 12, 2026
+1dSEC Form 4

Evidence

9
CA
Carter Bruce L ADirector
ENTAENANTA PHARMACEUTICALS INC
Grant or award
A—
20.0K sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC Form 4

Evidence

8
PB
Pfeiffenberger BrentDirector, President and CEO
IPSCCentury Therapeutics, Inc.
Tax withholding
F$151K
55.4K sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC Form 4

Evidence

8
TN
Tanious Jubran N.President & COO
SVVSavers Value Village, Inc.
Option exercise
M$141K
100.0K sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC Form 4

Evidence

8
FM
Fong MorganGENERAL COUNSEL & SECRETARY
CARTMaplebear Inc.
Open-market sale · 10b5-1 plan
SELL$186K
4,955 sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC Form 4

Evidence

6
CM
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.
ANIPANI PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$36K
500 sh
Mar 13, 2026Mar 13, 2026
traded Mar 13, 2026
+0dSEC Form 4

Evidence

5
RJ
Rishel JeremyChief Technology Officer
SOFISoFi Technologies, Inc.
Grant or award
A—
181.8K sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC Form 4

Evidence

5
SE
Schuppenhauer EricEVP GBUL Borrow
SOFISoFi Technologies, Inc.
Grant or award
A—
103.9K sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC Form 4

Evidence

5
MK
Mukkamala Himagiri KChief Operating Officer
QTWOQ2 Holdings, Inc.
Grant or award
A—
7,708 sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC Form 4

Evidence

5
CL
Coleman Kirk LChief Business Officer
QTWOQ2 Holdings, Inc.
Grant or award
A—
13.5K sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC Form 4

Evidence

5
KK
Keough KelliEVP, GBUL, SIPS
SOFISoFi Technologies, Inc.
Grant or award
A—
90.9K sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC Form 4

Evidence

5
CD
Chudova DaryaChief Technology Officer
GHGuardant Health, Inc.
Grant or award
A—
23.9K sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC Form 4

Evidence

5
CL
Coleman Kirk LChief Business Officer
QTWOQ2 Holdings, Inc.
Grant or award
A—
6,746 sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC Form 4

Evidence

5
KK
Kalia KumudChief Information Officer
GHGuardant Health, Inc.
Grant or award
A—
13.6K sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC Form 4

Evidence

5
CS
Campbell Elizabeth SExecutive Vice President
CORCencora, Inc.
Option exercise
M—
12.6K sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC Form 4

Evidence

5
CC
Cowan ChadChief Scientific Officer
IPSCCentury Therapeutics, Inc.
Tax withholding
F$3,907
1,431 sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC Form 4

Evidence

5
HT
Hamilton Brian TDirector, President of CCBX
CCBCOASTAL FINANCIAL CORP
Grant or award
A—
2,714 sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC Form 4

Evidence

5
PA
Pinto ArunChief Risk Officer
SOFISoFi Technologies, Inc.
Grant or award
A—
155.8K sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC Form 4

Evidence

5
CL
Coleman Kirk LChief Business Officer
QTWOQ2 Holdings, Inc.
Grant or award
A—
13.5K sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC Form 4

Evidence

4
LH
Lee Chan HenrySVP, General Counsel
ONCBeOne Medicines Ltd.
Option exercise · 10b5-1 plan
M$28K
133 sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC Form 4

Evidence

3
KS
Kerr Michael SGeneral Counsel
QTWOQ2 Holdings, Inc.
Grant or award · 10b5-1 plan
A—
18.3K sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC Form 4

Evidence

2
FC
Freeman ChrisChief Commercial Officer
GHGuardant Health, Inc.
Grant or award
A—
18.7K sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC Form 4

Evidence

0
KS
Kerr Michael SGeneral Counsel
QTWOQ2 Holdings, Inc.
Grant or award · 10b5-1 plan
A—
7,322 sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC Form 4

Evidence

0
LH
Lee Chan HenrySVP, General Counsel
ONCBeOne Medicines Ltd.
Option exercise · 10b5-1 plan
M—
1,274 sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC Form 4

Evidence

0
KS
Kerr Michael SGeneral Counsel
QTWOQ2 Holdings, Inc.
Grant or award · 10b5-1 plan
A—
7,322 sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC Form 4

Evidence

0
RS
Randhawa SimratEVP, Head of R&D
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M—
12.5K sh
Mar 12, 2026Mar 13, 2026
traded Mar 12, 2026
+1dSEC Form 4

Evidence

0
FM
Fong MorganGENERAL COUNSEL & SECRETARY
CARTMaplebear Inc.
Option exercise · 10b5-1 plan
M—
110.3K sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC Form 4

Evidence

0
KS
Kerr Michael SGeneral Counsel
QTWOQ2 Holdings, Inc.
Grant or award · 10b5-1 plan
A—
3,664 sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC Form 4

Evidence

0
LH
Lee Chan HenrySVP, General Counsel
ONCBeOne Medicines Ltd.
Option exercise · 10b5-1 plan
M—
1,430 sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC Form 4

Evidence

0
LH
Lee Chan HenrySVP, General Counsel
ONCBeOne Medicines Ltd.
Option exercise · 10b5-1 plan
M$16K
98 sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC Form 4

Evidence

0
EO
Espinoza OctavioChief Financial Officer
LGNDLIGAND PHARMACEUTICALS INC
Option exercise · 10b5-1 plan
M—
2,405 sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC Form 4

Evidence

0
RS
Randhawa SimratEVP, Head of R&D
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M—
5,000 sh
Mar 12, 2026Mar 13, 2026
traded Mar 12, 2026
+1dSEC Form 4

Evidence

0
RS
Randhawa SimratEVP, Head of R&D
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M—
7,998 sh
Mar 12, 2026Mar 13, 2026
traded Mar 12, 2026
+1dSEC Form 4

Evidence

0
LH
Lee Chan HenrySVP, General Counsel
ONCBeOne Medicines Ltd.
Option exercise · 10b5-1 plan
M$21K
110 sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC Form 4

Evidence

0
RS
Randhawa SimratEVP, Head of R&D
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M—
8,332 sh
Mar 12, 2026Mar 13, 2026
traded Mar 12, 2026
+1dSEC Form 4

Evidence

0
LH
Lee Chan HenrySVP, General Counsel
ONCBeOne Medicines Ltd.
Option exercise · 10b5-1 plan
M—
1,729 sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC Form 4

Evidence

0
RS
Randhawa SimratEVP, Head of R&D
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M$68K
7,998 sh
Mar 12, 2026Mar 13, 2026
traded Mar 12, 2026
+1dSEC Form 4

Evidence

0
EO
Espinoza OctavioChief Financial Officer
LGNDLIGAND PHARMACEUTICALS INC
Option exercise · 10b5-1 plan
M$223K
2,405 sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC Form 4

Evidence